VOICEMOD
15.6.2022 14:07:40 CEST | Business Wire | Press release
Voicemod (www.voicemod.net ), the world leader in augmented voice and interactive audio, is releasing its proprietary, first-of-its-kind voice conversion product powered by artificial intelligence (AI). This new collection of AI voices is a giant leap in innovation in developing speech-to-speech voice transformation capabilities. Voicemod empowers people to find their sonic and gender identity in digital spaces and create their personalized voice avatars — in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005160/en/
KEY POINTS
- AI voices unlock a previously impossible level of customization in online audio expression, furthering Voicemod’s mission to allow users to sound how they want to sound.
- The real-time speech-to-speech voice conversion engine makes it possible to create realistic synthetic voices while keeping facets of a user’s original voice such as emotion, accentuation, and pacing, creating unique sonic identities.
- This technology will enable Voicemod’s millions of users, ranging from gamers and roleplayers to people not comfortable with their voice, to better express themselves online.
Voicemod’s technology innovation in speech-to-speech voice conversion allows for personal customization or integration of the user’s personality. It offers people extensive freedom in how much of their natural voice they keep or mix, resulting in a unique, personalized voice avatar that fits their needs on a case-by-case basis for work or play.
Speech-to-speech AI-based voice technology not only expands the degree to which users can alter a source voice, but it also provides the ability to add or remove accents. Gamers and roleplayers can speak with an accurate re-creation of their favorite character, without the need for voice acting.
"This is a first step into the future. With further development of AI voices, it's not only going to help people like me in the trans community, it's going to change the meta of the world," said Kairi Caitlyn , a VTuber on Twitch and the world's top Spellbreak competitive player/coach, as well as an esports gaming community organizer.
The Voicemod AI voices, available now in beta mode, range from realistic-sounding human voices to ones with added effects to complete fantasy characters. For example, in addition to Voicemod’s masculine and feminine-sounding “Bob” and “Alice” voices, the celebrity-inspired “Morgan” voice offers fantasy characters such as Celestial, Narrator, The President, and The General. The technology launch contains multiple additional voices, combining both AI and classic sound design techniques to enable users to instantly turn into a pilot, an astronaut, and even digital entities, opening more creative possibilities than ever before.
“Voicemod AI Voices are lots of fun and give a richer experience for participants or for scenarios you're running your players through. Playing sci-fi? Grab that astronaut's voice! Want to sound like a deity? Morgan is your best bet. I can't wait to start using this for my sessions,” said Cypheroftyr , an American streamer and TTRPG DEI consultant and developer known as the founder and director of the non-profit organization I Need Diverse Games .
With real-time voice-to-voice conversion technology, Voicemod is creating an entirely new toolset with which people can explore their audio self-expression for more genuine person-to-person communication.
“We’re very excited to introduce the next stage in audio expression technology to our passionate community of Voicemod users — and to the rest of the world,” said Voicemod CEO and co-founder Jaime Bosch. “Integrating the power of real-time AI voices into our engine, combined with our growing catalog of IP partnerships, enables a previously impossible level of customization in audio expression online and in the metaverse.”
Voicemod is shaping the future of communication by building industry-leading social audio tools that make it easy for anyone to create, customize, enhance, and control the way they sound online, in social apps, and even in the metaverse. The company’s current suite of technology products already provides incredible capabilities to enthusiastic Voicemod users, with tools such as the recently launched PowerPitch technology for building realistic, persistent online voice identities for gaming, work, school, role-playing, or social communication.
Today, all Voicemod users can start experimenting with AI voices on their PCs, requesting their priority access at http://voicemod.net/ai-beta/ . Become a Voicemod user to find your true voice persona for more immersive, enjoyable, and entertaining gaming and communications online.
Resources
- Watch a short video for more details on AI voices.
- See the Voicemod newsroom for details on recent licensing agreements for popular intellectual property (IP) including games, emoticons, music, and TV titles.
- Consult the Voicemod Developer Kit —compatible for both PC and Mac— for platforms that support Voicemod technology, as well as how B2B developers, creators, and OEMs can integrate Voicemod's real-time voice conversion technology directly into their games, applications, social apps, and hardware to drive new levels of user engagement and retention.
About Voicemod
Voicemod is the leader in real-time audio augmentation. Developers trust Voicemod’s audio technology to help end-users create virtual voices and define their sonic identities. As companies strive to build a responsible metaverse, Voicemod is the tool that helps gamers, content creators, and professionals of all skill levels find the voice that best expresses themselves as they play, work, create, and entertain. Discover more at www.voicemod.net .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005160/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
